ALTSTATION.IO

Insulet Corporation (PODD) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$241.42

Change

-0.71%

Market Cap

$16.99B

Avg Volume

804.8K

Company Overview

Insulet Corporation develops and sells insulin delivery systems primarily for people with insulin-dependent diabetes. Their main products include the Omnipod platform, which features the Omnipod 5 and the Omnipod DASH systems. These products integrate technology for automated insulin delivery and management, leveraging Bluetooth connectivity to enhance patient experience. Insulet’s offerings are purchased by end-users through pharmacies and independent distributors, making them accessible to a wide range of patients in the U.S. and internationally.

Insulet is a leader in the insulin delivery market, particularly with its innovative Omnipod system. This competitive position is bolstered by the company’s proprietary technology, such as the AID algorithm, which provides automated insulin delivery based on real-time glucose data. However, it faces competition from established players like Medtronic and newer entrants focusing on similar automation technologies. Market dynamics, including increasing diabetes prevalence and a growing push for patient-centric solutions, support Insulet’s growth but also heighten competitive pressures.

Currently, Insulet is on a growth trajectory, fueled by strong demand for its insulin delivery products. In 2023, the company reported a revenue increase of approximately 20% year-over-year, driven by the rollout of their Omnipod 5 system. With ongoing enhancements to their technology and strategic partnerships, including those involving other pharmaceutical firms, Insulet is well-positioned to capitalize on the expanding diabetes care market.

Key Financials

Market Cap

$16.99B

Revenue

$2.52B

EBITDA

$510.90M

Gross Margin

70.9%

Profit Margin

9.8%

Revenue Growth

29.9%

Total Cash

$757.40M

Total Debt

$1.08B

Free Cash Flow

$215.34M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

70.38

Forward P/E

39.07

Beta

1.42

52-Week High

$354.88

52-Week Low

$230.05

EPS

$3.43

50-Day Avg

$287.86

200-Day Avg

$304.92

Price/Book

12.27

Technical Analysis

Over the past 52 weeks, Insulet Corporation (PODD) has displayed a bearish trend, primarily characterized by a steady decline from a peak around $360 in August 2022 down to its current level of $241.42. Key support exists at $240, which has been tested multiple times, indicating buyer interest, while resistance is observed at the $280 mark, suggesting it may be difficult for the stock to re-enter the previous trading range. Notably, a downtrend line has formed, reinforcing the strength of the overall bearish sentiment. Recent momentum has shown weakness, with the stock continuing to struggle below both the 50-day and 200-day moving averages, indicating persistent selling pressure. The current price is near the lower end of the 52-week range, which implies heightened risk and suggests that the stock may continue to face challenges moving forward without a change in market sentiment or fundamentals.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Insulet Corporation (PODD) stock from the past week:

1. Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East

Insulet Corporation announced on February 6, 2026, the expansion of its global footprint with the launch of its Omnipod 5 Automated Insulin Delivery (AID) System in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates. Alongside Omnipod 5, the company also introduced Omnipod Discover, a new data analytics and reporting platform designed to streamline diabetes management for users, caregivers, and healthcare providers. These launches aim to transform diabetes care in the region and are part of Insulet’s strategy to expand the Omnipod ecosystem.

2. Insulet Awarded $15 Million in Attorney Fees Following Trade Secrets Victory

A Massachusetts federal judge ruled on February 6, 2026, that Insulet Corp. is entitled to an additional $15 million in attorney fees. This award comes after Insulet secured a $59.4 million victory against EOFlow Co. Ltd. in a trade secrets dispute concerning insulin pump technology. The judge determined that EOFlow willfully stole trade secrets, justifying the award of attorney fees under the Defend Trade Secrets Act.

Market Sentiment and Analyst Recommendations

Bull Case

Insulet is growing revenue at 29.9% annually in a massive market–diabetes management isn’t a niche. The Omnipod ecosystem is expanding aggressively with launches in Saudi Arabia, Kuwait, Qatar, and the UAE this week, opening high-margin international markets that barely register in current revenue. The company just won a $59.4 million trade secrets lawsuit against EOFlow with an additional $15 million in attorney fees awarded, eliminating a competitive threat and validating Insulet’s technology moat. At 70x forward earnings the valuation looks stretched, but 25 analysts see upside to $369.64 (53% above current price), and the consensus range tops out at $450. The balance sheet is clean with $757M in cash against $1.08B debt, giving runway to fund growth. Q4 earnings on February 18 will likely show continued momentum before the stock reports.

Bear Case

The stock is down 17.4% in 30 days and 15.5% over the past year for good reason–the 70x P/E is indefensible for a hardware company unless growth accelerates dramatically. Insulet is trading near the 52-week low of $230, and the technical setup is broken: price sits below both the 50-day and 200-day moving averages with a downtrend line in place since August 2022. Recent analyst moves tell the story: TD Cowen downgraded from buy to hold, Barclays cut its target from $316 to $274 (below current price), and even Stifel lowered guidance from $370 to $350. The NXP supplier agreement extension announcement reveals nothing about terms or duration, which is a red flag for cost pressures. Recurring revenue from pump supplies masks that hardware adoption faces saturation in mature markets, and international expansion doesn’t move the needle fast enough to justify current multiples.

What to Watch

Q4 earnings on February 18 are critical–watch for guidance on 2026 revenue growth and gross margins. If growth guidance dips below 25% or if management signals pricing pressure from the NXP renegotiation, expect another leg down. Monitor the $280 resistance level; a break above it would signal technical reversal, but failure to hold $240 support suggests $220 is next. Track Omnipod 5 adoption rates in the Middle East and Europe over the next two quarters–if these launches don’t materially move needle within 6 months, the international expansion thesis collapses. Watch analyst revisions closely: if Stifel, JP Morgan, or other major firms follow Barclays and Cowen lower, institutional money will exit. Finally, pay attention to competitive positioning against Tandem Diabetes (TNDM) and Medtronic (MDT)–any share loss in the AID market is a death knell for this valuation.

Analyst Consensus

STRONG BUY

Based on 25 analyst opinions

Low Target

$274.00

Mean Target

$369.64

High Target

$450.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

3,900

Earnings & Dividends

Next Earnings

Feb 18, 2026

EPS (Trailing)

$3.43

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is PODD a good stock to buy?

Yes, based on the current analyst recommendation of STRONG BUY and a target price of $369.64, PODD presents a significant upside potential from its current price of $241.42. Investors in the medical device sector could benefit from its growth trajectory.

What is PODD’s price target?

Analysts have set a price target of $369.64 for Insulet Corporation. This represents an upside of approximately 53% from the current market price, signaling strong future performance expectations.

Does PODD pay a dividend?

No, Insulet Corporation does not pay a dividend. Investors looking for income through dividends will need to look elsewhere, but the growth potential may offset this for some investors.

What is the P/E ratio of PODD?

The current P/E ratio for Insulet Corporation is 70.38, which indicates that investors are paying a high price for earnings. This can be justified by strong growth prospects but also suggests that the stock could be overvalued if growth slows.

What has been the 52-week range for PODD?

PODD has traded between $230.05 and $354.88 over the past year. This indicates volatility but also highlights areas where investors might find buy opportunities during dips.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.